Skip to main content

Neuromyelitis Optica Spectrum Disorders

Ophthalmology
4
Pipeline Programs
7
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 4 programs with unclassified modality

Ophthalmology is a $3.7B market with a mature, consolidating portfolio dominated by glaucoma treatments and emerging corneal/retinal therapies.

$3.7B marketMature→ Stable30 products15 companies

Key Trends

  • Glaucoma therapeutics (prostaglandin analogs, adrenergic agents) represent 60%+ of spending but face patent cliffs 2028-2034
  • Innovative mechanisms (NGF agonists, LFA-1 antagonists, RTKIs) gaining traction in dry eye and retinal disease segments
  • Heavy trial activity (2,656 total) skewed toward Phase 4 (369) and Phase 3 (442), indicating mature clinical development landscape

Career Verdict

Ophthalmology offers stable mid-career opportunities with strong Commercial and Medical Affairs salaries, but limited innovation catalysts and significant patent cliff risk warrant careful timing of entry.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1LUMIGANDeclining
$697M
AbbVie·LOE_APPROACHING
#2OXERVATEStable
$493M
Unspecified·PEAK
#3XIIDRAStable
$473M
Bausch + Lomb·PEAK7.6yr
#4INLYTAGrowing
$467M
Pfizer·PEAK11.2yr
#5HUMIRADeclining
$258M
AbbVie·LOE_APPROACHING

Drug Class Breakdown

Prostaglandin Analogs (Bimatoprost)
$697M(19%)

mature, losing exclusivity

Nerve Growth Factor Agonists
$493M(13%)

peak growth in corneal disease

LFA-1 Antagonists (Dry Eye)
$473M(13%)

sustained peak sales

Receptor Tyrosine Kinase Inhibitors
$467M(13%)

expanding in retinal indications

Alpha-2 Adrenergic Agonists
$362M(10%)

mature, multiple LOE approaching

Combination Therapies (Brimonidine/Timolol)
$232M(6%)

mature, losing exclusivity

Complement Inhibitors
$223M(6%)

mature immunology approach

Career Outlook

Stable

Ophthalmology offers predictable mid-career growth with strong Commercial ($158K) and Medical Affairs ($247K) compensation but faces structural headwinds: patent cliffs 2028-2034 eliminate $97M in revenue, glaucoma franchise maturity limits blockbuster potential, and modest trial volume (2,656) signals incremental R&D expansion. Best suited for professionals seeking stable roles in established therapeutic areas rather than disruptive innovation.

Breaking In

Enter via Clinical Operations or Commercial analyst roles at CROs (Syneos 210 jobs) or large diagnostics players (Labcorp 904) to build domain expertise before targeting pharma MSL/Medical Affairs positions.

For Experienced Professionals

Experienced professionals should prioritize Medical Affairs and Market Access roles leveraging mature market knowledge; avoid product-specific expertise in glaucoma due to patent cliff concentration, and consider adjacent areas (retinal, corneal) where innovation catalysts remain.

In-Demand Skills

Glaucoma/dry eye clinical expertise and key opinion leader relationshipsRegulatory navigation for mature small-molecule formulations and device combinationsMarket access and reimbursement strategy (high generic/biosimilar pressure)

Best For

Medical Science Liaison (MSL) — strong $247K average salary, KOL interface criticalCommercial/Brand Manager — competitive $158K salaries, established product lifecycle managementClinical Operations Manager — high hiring volume (409 jobs), trial coordination in Phase 4-heavy pipeline

Hiring Landscape

$59K-$247K

Ophthalmology hiring (3,202 jobs) is distributed across diagnostics/devices (Labcorp 904, Abbott 348) and pharma commercial functions rather than concentrated in R&D. Top pharmaceutical employers (Pfizer 60, AstraZeneca 100, Regeneron 168) show modest pharma-specific headcount relative to market size, suggesting outsourced CRO and distributor dependency. Medical Affairs ($247K avg salary) commands premium compensation, signaling high barrier to entry but strong mid-career upside.

3,202
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

904Growing
348Stable
168Growing
219Stable

By Department

Clinical Operations(13%)
$150K
Commercial(10%)
$158K
Medical Affairs(3%)
$247K
R&D(6%)
$145K
Engineering(9%)
$112K

Clinical Operations and Commercial roles offer entry-level stability ($150K-$158K); Medical Affairs commands premium salaries ($247K) but requires advanced credentials; limited R&D hiring (207 jobs) suggests constrained innovation investment.

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Biocad
BiocadRussia - St. Petersburg
1 program
1
divozilimabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT05730699Active Not Recruiting105Est. Sep 2026
Bio-Thera Solutions
Bio-Thera SolutionsChina - Guangzhou
1 program
1
BAT4406FPhase 1
Biocorp
BiocorpFrance - Issoire
1 program
1
BAT4406FPhase 11 trial
Active Trials
NCT04146285Completed15Est. Dec 2023
iRegene Therapeutics
1 program
1
Extracellular vesicles derived from human-induced neural stem cells for intrathecal injectionPhase 11 trial
Active Trials
NCT06620809Recruiting69Est. Nov 2027
MyBiotech
MyBiotechGermany - Überherrn
1 program
An Diagnostic Cohort on AQP4-Immunoglobulin G Detection KitN/A1 trial
Active Trials
NCT04388072Completed200Est. Feb 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Biocaddivozilimab
iRegene TherapeuticsExtracellular vesicles derived from human-induced neural stem cells for intrathecal injection
BiocorpBAT4406F
MyBiotechAn Diagnostic Cohort on AQP4-Immunoglobulin G Detection Kit

Clinical Trials (4)

Total enrollment: 389 patients across 4 trials

Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)

Start: Dec 2022Est. completion: Sep 2026105 patients
Phase 3Active Not Recruiting
NCT06620809iRegene TherapeuticsExtracellular vesicles derived from human-induced neural stem cells for intrathecal injection

The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders

Start: Mar 2025Est. completion: Nov 202769 patients
Phase 1Recruiting

A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

Start: Sep 2020Est. completion: Dec 202315 patients
Phase 1Completed
NCT04388072MyBiotechAn Diagnostic Cohort on AQP4-Immunoglobulin G Detection Kit

An Diagnostic Cohort on AQP4-Immunoglobulin G Detection Kit

Start: May 2020Est. completion: Feb 2021200 patients
N/ACompleted

Related Jobs in Ophthalmology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 389 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.